Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 12, 2013, Pages 2606-2612

  Mato, Anthony ^a   Feldman, Tatyana ^a   Zielonka, Tania ^a   Singavi, Arun ^a   Gadaletta, Gabriella ^a   Waksmundzki, Kathryn ^a   Bhattacharyya, Pritish ^a   Chow, Kar Fai ^a   Yang, Xiao ^a   Panush, David ^a   Agress, Harry ^a   Rosario, Maria ^a   Howlett, Christina ^a,b   Pecora, Andrew ^a   Goy, Andre ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Chemotherapeutic approaches; Diffuse large B cell lymphoma; DLBCL; Immunotherapeutic approaches; Lymphoma and Hodgkin disease

Indexed keywords

ALLOPURINOL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; METHOTREXATE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; FOLLOW UP; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; ONCOGENE C MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84887220617     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.783909     Document Type: Article

References (42)

1. Fisher RI, Gaynor ER, Dahlberg S, et al . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin' s lymphoma . N Engl J Med 1993; 328: 1002-1006 .
2. Thieblemont C, Van Den Neste E, et al . Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d' Etudes des Lymphomes de l' Adulte . Blood 2010; 116: 2040-2045.
3. Pfreundschuh M, Trumper L, Osterborg A, et al . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diff use large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group . Lancet Oncol 2006; 7: 379-391.
4. Lossos I S, M orgensztern D . P rognostic biomarkers in diff use large B-cell lymphoma . J Clin Oncol 2006 ; 24 : 995-1007 .
5. Hans CP, Weisenburger DD, Greiner TC, et al . Confi rmation of the molecular classifi cation of diff use large B-cell lymphoma by immunohistochemistry using a tissue microarray . Blood 2004 ; 103 : 275-282 .
6. Sehn LH, Berry B, Chhanabhai M, et al . The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diff use large B-cell lymphoma treated with R-CHOP . Blood 2007 ; 109 : 1857-1861 .
7. Savage KJ, Johnson NA, Ben-Neriah S, et al . MYC gene rearrangements are associated with a poor prognosis in diff use large B-cell lymphoma patients treated with R-CHOP chemotherapy . Blood 2009 ; 114 : 3533-3537 .
8. Cheson BD, Pfistner B, Juweid ME, et al . Revised response criteria for malignant lymphoma . J Clin Oncol 2007 ; 25 : 579-586 .
9. Gottlieb JA, Gutterman JU, McCredie KB, et al . Chemotherapy of malignant lymphoma with adriamycin. Cancer Res 1973; 33: 3024-3028.
10. Habermann T, et a l. R ituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diff use large B-cell lymphoma . J Clin Oncol 2006 ; 24 : 3121-3127 .
11. Gisselbrecht C, Glass B, Mounier N, et al . R-ICE versus R-DHAP in relapsed patients with CD20 diff use large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study . J Clin Oncol 2009 ; 27(15 Suppl.) : Abstract 8509 .
12. Thieblemont C, B riere J, M ounier N, et a l. The germinal center/activated B-cell subclassifi cation has a prognostic impact for response to salvage therapy in relapsed/refractory diff use large B-cell lymphoma: a Bio-CORAL study . J Clin Oncol 2011 ; 29 : 4079-4087 .
13. Poeschel V, Nickelsen M, Hanel M, et al . Dose-dense rituximab in combination with biweekly CHOP-14 for elderly patients with diff use large B-cell lymphoma (DLBCL): results of a phase-I/II and pharmacokinetic study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2006; 108(Suppl. 1): Abstract 2738 .
14. Wilson W H, D unleavy K, P ittaluga S, et a l. D A-EPOCH-R is highly eff ective in both BCL-6-and BCL-6 untreated de novo diff use large B-cell lymphoma (DLBCL): study update and analysis of survival outcomes for multiple biomarkers . Blood 2006 ; 108(Suppl. 1) : Abstract 206.
15. Wilson W H, D unleavy K, P ittaluga S, et a l. D ose-adjusted EPOCHrituximab is highly eff ective in the GCB and ABC subtypes of untreated diff use large B-cell lymphoma . Blood 2004; 104(Suppl. 1): Abstract 159.
16. Fayad L, Pro B, Hagemeister F, et al . R-HCVAD/R-MTX-ARAC is an eff ective regimen for untreated diff use large B-cell lymphoma (DLBCL) with aggressive features in patients younger than 60 years . Blood 2007; 110(Suppl. 1): Abstract 1285.
17. Recher C, Coiffi er B, Haioun C, et al . A prospective randomized study comparing dose intensive immunochemotherapy with R-ACVBP vs standard R-CHOP in younger patients with diff use large B-cell lymphoma (DLBCL). Groupe d' Etude Des Lymphomes De l' Adulte (GELA) Study LNH03-2B . Blood 2010 ; 116(Suppl. 1) : Abstract 109 .
18. Vitolo U, C abras M G, R ossi G, et a l. R ituximab as adjuvant to dose-dense and high dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) as fi rst line treatment in stage III-IV diff use large B-cell lymphoma (DLBCL) at poor prognosis: fi nal analysis of phase II GIMURELL trial . Blood 2006 ; 108(Suppl. 1) : Abstract 329 .
19. Borate U, S teciuk M, A lexander K, et a l. H igh-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may overcome adverse prognosis in patients with diff use large B-cell lymphoma (DLBCL) with an activated B-cell (ABC) molecular profi le . J Clin Oncol 2011; 29(15 Suppl.): Abstract e18522.
20. Nowakowski GS, Reeder CB, LaPlant B, et al . Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: a phase I/II study . J Clin Oncol 2011 ; 29(15 Suppl.): Abstract 8015.
21. Dunleavy K, Janik J, Gea-Banacloche J, et al . Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma . Blood 2004; 104(Suppl. 1): Abstract 1385.
22. Leonard JP, Furman RR, Cheung Y-KK, et al . Phase I/II trial of bortezomib-CHOP-rituximab in diff use large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results . Blood 2005 ; 106(Suppl. 1): Abstract 491.
23. Micallef INM, Maurer MJ, Wiseman GA, et al . Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diff use large B-cell lymphoma . Blood 2011; 118: 4053-4061.
24. Hagemeister FB . Maintenance and consolidation strategies in non-Hodgkin' s lymphoma: a review of the data . Curr Oncol Rep 2010 ; 12 : 395-401 .
25. Pfreundschuh M, Held G, Zeynalova S, et al . Improved outcome of elderly poor-prognosis DLBCL patients with 6xCHOP-14 and 8 applications of rituximab (R) given over an extended period: results of the SMARTE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) . Blood 2011 ; 118 : Abstract 592 .
26. Cuccuini W, Briere J, Mounier N, et al . MYC-diff use large B cell lymphomas (DLBCL) treated in randomized prospective salvage therapy, RICE or RDHAP followed by BEAM plus autologous stem cell transplantation (ASCT) . A BioCORAL report. Blood 2011 ; 118(Suppl. 1) : Abstract 594 .
27. Barrans S, Crouch S, Smith A, et al . Rearrangement of MYC is associated with poor prognosis in patients with diff use large B-cell lymphoma treated in the era of rituximab . J Clin Oncol 2010 ; 28 : 3360-3365 .
28. Riihijarvi S, Nyman H, Holte H, et al . High serum vascular endothelial growth factor (VEGF) level is an adverse prognostic factor in high risk diff use large B-cell lymphoma (DLBCL) patients treated with dose-dense chemoimmunotherapy and Systemic CNS prophylaxis . Results from a Nordic phase II study. Blood 2010 ; 116(Suppl. 1): Abstract 4142.
29. Maurer MJ, Micallef INM, Cerhan JR, et al . Elevated serum free light chains are associated wiThevent-free and overall survival in two independent cohorts of patients with diff use large B-cell lymphoma . J Clin Oncol 2011 ; 29 : 1620-1626 .
30. Shaknovich R, Geng H, Johnson NA, et al . DNA methylation signatures defi ne molecular subtypes of diff use large B-cell lymphoma . Blood 2010 ; 116 : e81-e89 .
31. Alizadeh AA, Gentles AJ, Alencar AJ, et al . Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment . Blood 2011 ; 118 : 1350-1358 .
32. Li C, Kim S-W, Rai D, et al . Copy number abnormalities, MYC activity, and the genetic fi ngerprint of normal B cells mechanistically defi ne the microRNA profi le of diff use large B-cell lymphoma . Blood 2009 ; 113 : 6681-6690 .
33. Montes-Moreno S, M artinez N, S anchez-Espiridin B, et a l. miRNA expression in diff use large B-cell lymphoma treated with chemoimmunotherapy. Blood 2011; 118: 1034-1040.
34. Lee N-R, Song E-K, Jang KY, et al . Prognostic impact of tumor infi ltrating FOXP3 positive regulatory T cells in diff use large B-cell lymphoma at diagnosis . Leuk Lymphoma 2008; 49: 247-256.
35. Mato AR, Feldman T, Zielonka T, et al . R-HCVAD/R-MTX-Arac (R-HCVAD) overcomes risk features associated with inferior outcomes in the treatment of newly diagnosed, high-risk diff use large B-cell lymphoma (DLBCL) . Blood 2010 ; 116(Suppl. 1) : Abstract 1782 .
36. Purroy N, B ergua J, G allur L, et a l. D ose-adjusted EPOCH plus rituximab in untreated patients with poor prognosis large B-cell, with analysis of germinal center and activated B-cell biomarkers . A phase IV study conducted by the Spanish PETHEMA group. Blood 2011; 118(Suppl. 1): Abstract 593.
37. Purroy N, Lopez A, Vallespi T, et al . Dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor risk large B-cell lymphoma . A phase 2 study conducted by the Spanish PETHEMA group . Blood 2009;114(Suppl. 1): Abstract 2701.
38. Molina TJ, Canioni D, Copie-Bergman C, et al . R-ACVBP benefi ts to younger patients with non-germinal centre diff use large B-cell lymphoma as compared to R-CHOP in the GELA trial LNH03-2B . Blood 2011 ; 118(Suppl. 1) : Abstract 2632 .
39. Kantarjian H M, O' B rien S, S mith T L, et a l. R esults of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia . J Clin Oncol 2000 ; 18 : 547-561 .
40. Romaguera JE, Fayad L, Rodriguez MA, et al . High rate of durable remissions after treatment of newly diagnosed aggressive mantlecell lymphoma with rituximab plus Hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine . J Clin Oncol 2005 ; 23 : 7013-7023 .
41. Wildes TM, Farrington L, Yeung CCS, et al . Hyper-CVAD and rituximab-hyperCVAD in Burkitt lymphoma (BL): a multi-institutional experience . J Clin Oncol 2011 ; 29(15 Suppl.): Abstract e18541.
42. Thomas DA, Cortes J, O' Brien S, et al . Hyper-CVAD program in Burkitt' s-type adult acute lymphoblastic leukemia . J Clin Oncol 1999 ; 17 : 2461-2470 .